Distribution of clusters and eligible patients in the standard care and intervention arms of the trial
| Standard care | Intervention | |
|---|---|---|
| N clusters | 79 | 76 |
| Region (n clusters) | ||
| South East | 4 | 3 |
| London | 18 | 16 |
| East of England | 17 | 16 |
| South West | 9 | 8 |
| West Midlands | 1 | 3 |
| East Midlands | 12 | 12 |
| North East and North West | 4 | 3 |
| Yorkshire and the Humber | 14 | 15 |
| Clinical software or iPLATO user | ||
| CPRD | 1 | 2 |
| TPP SystmOne | 61 | 59 |
| iPLATO | 10 | 10 |
| N patients at-risk | 51 136 | 51 121 |
| Median (minimum, maximum) at-risk patients per cluster | 583 (125, 1678) | 637 (79, 3022) |
| Sex, n (%)* | ||
| Men | 24 420 (51.2) | 24 182 (51.2) |
| Women | 23 285 (48.8) | 23 005 (48.8) |
| Age group, n (%)* | ||
| 18–34 | 8113 (17.0) | 8216 (17.4) |
| 35–50 | 16 197 (34.0) | 15 797 (33.5) |
| 51–64 | 23 395 (49.0) | 23 174 (49.1) |
| Risk group, n (%)† | ||
| Chronic heart disease | 8419 (16.5) | 8291 (16.2) |
| Diabetes | 12 999 (25.4) | 13 370 (26.2) |
| Chronic respiratory disease | 24 244 (47.4) | 24 393 (47.7) |
| Chronic liver disease | 1728 (3.4) | 1605 (3.1) |
| Chronic kidney disease | 3190 (6.2) | 3045 (6.0) |
| Chronic neurological disease | 5949 (11.6) | 5853 (11.4) |
| Immunosuppression | 3341 (6.5) | 3766 (7.4) |
*From patient-level data, based on 145 practices (N=94 892; 47 705 standard care, 47 187 intervention).
†Groups not exclusive.
CPRD, Clinical Practice Research Datalink.